Bildkälla: Stockfoto

Fluoguide: Critical catalysts for FG001 in 2023e - Redeye

Redeye comments on Fluoguide’s Q3 2022 report at a time when the company is approaching multiple critical catalysts in the coming 12 months. We judge that the company is making solid clinical progress and make some technical adjustments to our model.

Redeye comments on Fluoguide’s Q3 2022 report at a time when the company is approaching multiple critical catalysts in the coming 12 months. We judge that the company is making solid clinical progress and make some technical adjustments to our model.
Börsvärldens nyhetsbrev
ANNONSER